SOPH: Higher Future P/E Assumptions Will Support Upside Potential

Analysts lifted their price target on SOPHiA GENETICS by about $0.33 to $8.00, citing updated assumptions around fair value, discount rate, and future P/E that reflect recent research from multiple firms.

Analyst Commentary

Recent Street research has pointed to updated assumptions around fair value, the discount rate, and forward P/E as the main drivers behind the refreshed $8.00 price target on SOPHiA GENETICS. While details are brief, the tone of the reports suggests a mix of optimism around execution potential and caution around what needs to go right for the thesis to hold.

Bullish Takeaways

Bullish analysts are tying their higher targets to revised fair value models that incorporate updated P/E assumptions, signaling increased confidence in how the company could be valued if it meets its operational goals.
The willingness to lift price targets, even modestly by about $0.33 to $1 in recent research, suggests that the latest information has not weakened the thesis around the business model or growth opportunity.
Revisions to the discount rate in these models point to an improved view of risk around execution and cash flows, which supports a higher theoretical valuation for the shares.
By clustering around an $8.00 fair value, bullish analysts are providing investors with a clearer reference point for assessing upside potential relative to current trading levels.

Bearish Takeaways

Even with higher targets, the adjustments have been relatively modest, which suggests bullish analysts may still see limits to upside until there is more visibility on execution and financial performance.
The focus on discount rate and P/E assumptions highlights that a meaningful part of the thesis rests on modeling inputs rather than reported results, which can increase sensitivity to any negative surprises.
Reliance on future P/E to support fair value means the valuation case is closely tied to expectations about profitability, leaving less room for error if margins or growth trends do not line up with forecasts.
The need to update fair value frameworks across multiple firms at the same time underscores that the story is still in a refining phase, and investors may face bouts of volatility as assumptions are revisited.

What's in the News

Mount Sinai Health System will adopt the AI powered SOPHiA DDM Platform to support cancer research and genomic testing for more than 4,000 oncology patients a year, with a focus on NGS for blood cancers and solid tumors, while aiming to streamline workflow and interpretation time (Strategic Alliances, American Association for Cancer Research Annual Meeting).
Mount Sinai plans to use SOPHiA DDM for Blood Cancers and SOPHiA DDM for Solid Tumors, joining more than 990 institutions on SOPHiA GENETICS' decentralized platform and adding to the company's global network in precision medicine (Strategic Alliances).
SOPHiA GENETICS reaffirmed revenue guidance for fiscal 2026 at US$92 million to US$94 million, which the company states represents about 20% to 22% year over year growth compared with fiscal 2025 (Corporate Guidance).
Two of the largest U.S. healthcare systems joined the SOPHiA GENETICS network to use the AI native, cloud based SOPHiA DDM for Enhanced Exome, initially targeting genomic testing for up to 60,000 patients a year across the West Coast and Midwest (Client Announcements).
The two new U.S. health system partners, which collectively handle millions of genetic samples a year, aim to use SOPHiA DDM to support hereditary cancer and rare disease testing, manage turnaround times, and support research and innovation initiatives (Client Announcements).

Valuation Changes

Fair Value: $7.67 to $8.00, a small upward adjustment in the modeled share value.
Discount Rate: 8.53% to about 8.46%, a slight reduction in the rate used to discount future cash flows.
Revenue Growth: 21.50% to about 21.50%, effectively unchanged in the latest assumptions.
Net Profit Margin: 6.37% to about 5.62%, a modest reduction in projected profitability levels.
Future P/E: 96.65x to about 114.05x, a higher multiple being applied to expected earnings in the updated model.

3 views

Key Takeaways

Rapid platform adoption and high-value partnerships are fueling recurring revenue growth, expanding usage, and opening new verticals for SOPHiA GENETICS.
Process efficiencies and automation are driving margin improvements and setting the company on a path toward profitability and greater operating leverage.
Persistent unprofitability, customer concentration, currency risks, competition, and stricter regulations threaten growth prospects, market share, and the ability to scale internationally.

Catalysts

About SOPHiA GENETICS

Operates as a cloud-native software technology company in the healthcare space.What are the underlying business or industry changes driving this perspective?

The accelerating adoption of precision medicine and personalized healthcare is directly driving record new customer signings for SOPHiA GENETICS, particularly among large academic medical centers and central labs globally, setting up strong future recurring revenue growth as these customers ramp implementations and usage of the SOPHiA DDM platform.
The exponential expansion in healthcare data generation, combined with increasing demand for interoperable, cloud-based analytics platforms, is enabling SOPHiA GENETICS to upsell higher-value multimodal applications (like MSK-ACCESS and enhanced exome products), leading to rising ASPs, higher average contract values, and improved gross and net margins over time.
SOPHiA GENETICS' major new multiyear partnership with AstraZeneca to deploy AI-powered predictive models and real-world data analytics is a significant forward-looking catalyst, expected to contribute meaningfully to topline revenue from late 2025 into 2026 and to validate the platform for additional large biopharma partnerships in the future.
The increasing integration of multimodal data analytics (genomics, radiomics, clinical) onto the SOPHiA DDM platform is unlocking new verticals, driving higher adoption and usage per customer, and supporting a visible pipeline/backlog, which should drive sustained improvements in earnings and net margins as scale builds.
Ongoing process improvements, automation, and cost discipline are materially lowering cash burn and enhancing gross margins (adjusted gross margin improved to 74.4%), positioning SOPHiA GENETICS for operating leverage and progression toward positive adjusted EBITDA and profitability over the next 2–3 years.

SOPHiA GENETICS Earnings and Revenue Growth

SOPHiA GENETICS Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming SOPHiA GENETICS's revenue will grow by 21.5% annually over the next 3 years.
Analysts are not forecasting that SOPHiA GENETICS will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate SOPHiA GENETICS's profit margin will increase from -102.2% to the average US Healthcare Services industry of 5.6% in 3 years.
If SOPHiA GENETICS's profit margin were to converge on the industry average, you could expect earnings to reach $7.8 million (and earnings per share of $0.09) by about April 2029, up from -$79.0 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 115.1x on those 2029 earnings, up from -4.4x today. This future PE is greater than the current PE for the US Healthcare Services industry at 30.5x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.46%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent losses, increasing operating expenses, and continued adjusted EBITDA losses heighten pressure on SOPHiA GENETICS' path to profitability, raising the risk of shareholder dilution and limiting future R&D investment (impacts net margins and long-term earnings).
Heavy reliance on ongoing large customer signings and a relatively small core customer base increases concentration risk; loss of major accounts, slower-than-expected implementations, or inability to convert backlog could cause revenue growth to stall or reverse (impacts topline revenue and revenue growth rate).
Exposure to significant foreign exchange volatility-given most expenses are in Swiss francs/euros while reporting is in US dollars-creates unpredictable swings in reported results and could mask underlying margin weakness in unstable macro environments (impacts reported net margins and earnings consistency).
Intensifying competition in rare disease and oncology genomics, including recent competitor acquisitions to expand OUS (outside US) market presence, threatens SOPHiA GENETICS' pricing power, customer retention, and market share, potentially leading to increased churn and lower average revenue per user (impacts gross margins and revenue).
Broad secular risks such as stricter global data protection regulations, increased compliance costs, and geopolitical tensions restricting data sharing could hamper SOPHiA GENETICS' ability to scale worldwide, driving up costs and limiting international revenue expansion (impacts revenue growth and operating margins).

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $8.0 for SOPHiA GENETICS based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $9.0, and the most bearish reporting a price target of just $7.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $138.6 million, earnings will come to $7.8 million, and it would be trading on a PE ratio of 115.1x, assuming you use a discount rate of 8.5%.
Given the current share price of $4.87, the analyst price target of $8.0 is 39.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on SOPHiA GENETICS?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Precision Medicine Advances Will Transform Global Healthcare Analytics